NICE draft negative on Yondelis in soft tissue sarcoma
This article was originally published in Scrip
Executive Summary
Preliminary guidance from the National Institute for health and Clinical Excellence (NICE) suggests that PharmaMar's Yondelis (trabectedin) will not be widely used in the national health service in England and Wales to treat advanced soft tissue sarcoma.